RxDoctor Payments DataLook up a doctor →

Jack Schim, MD

Neurology · Carlsbad, CANPI 1346276375

Payments from drug & device makers

$1,960,518in general payments, 2019–2025

Across 2,156 payments — averaging $909.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$584K
  • Lilly USA, LLC$253K
  • Teva Pharmaceuticals USA, Inc.$214K
  • Amgen$208K
  • H. Lundbeck A S$199K
  • Ipsen Innovation$105K
  • plus $399K from 43 others

What the payments were for

  • Consulting fees$328,03419%
  • Speaking & faculty fees$1,176,90369%
  • Grants$1290%
  • Travel & lodging$160,6109%
  • Food & beverage$37,9142%
  • Education$2800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,960,518 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$1,504,045
Medicare patients
425
Services billed
207,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate100$189,601
BotoxOnabotulinumtoxina103$136,151
UbrelvyUbrogepant72$105,442
Aimovig AutoinjectorErenumab-Aooe95$100,557
Emgality PenGalcanezumab-Gnlm84$84,468
QuliptaAtogepant48$50,067
Zembrace SymtouchSumatriptan Succinate27$39,739
LamictalLamotrigine13$17,136
TreximetSumatriptan Succ/Naproxen Sod11$13,575
Eletriptan HbrEletriptan Hydrobromide39$6,907
Sumatriptan Succinate240$4,759
Naratriptan Hcl124$3,567
Diazepam28$3,195
Fentanyl20$3,065
Gabapentin63$2,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy, Qulipta$583,713$291,660223 claims
PfizerNurtec Odt$19,636$189,601100 claims
Upsher-smith Laboratories LLCZembrace Symtouch, Topiramate$26,398$40,553100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.

Other neurology in Carlsbad

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →